LENSAR, Inc.
LNSR Healthcare Medical Devices
LENSAR, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $58.4 million, up 9.24% from fiscal 2024. In the quarter to June 2026, revenue grew 18.4%, EPS grew 291.7% and free cash flow grew 96.8%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
Follow LNSR
LENSAR, Inc. (LNSR) P/E ratio
As of 16 October 2026, LENSAR, Inc. (LNSR) trades at a P/E ratio of 2.0×. Over the past ten years it has ranged from 0.0× (March 2026) to 3.2× (August 2026); the current reading is higher than 92% of that period. That is below the Medical Devices industry median of 23.2× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 2.0× | (18.93%) |
| Mar 2026 | 2.5× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 24 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| HYPR Hyperfine, Inc. compare | n/m |
| ECOR electroCore, Inc. compare | n/m |
| MYO Myomo, Inc. compare | n/m |
| SERA Sera Prognostics, Inc. compare | n/m |
| LUCD Lucid Diagnostics Inc. compare | n/m |
| ZOMDF Zomedica Corp. compare | n/m |
| LUNG Pulmonx Corporation compare | n/m |
| OM Outset Medical, Inc. compare | n/m |
| LNSR LENSAR, Inc. | 2.0× |
| Medical Devices industry median | 23.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)